Publications by authors named "Zoe Backholer"
Article Synopsis
- - Rucaparib is a potent oral inhibitor of PARP 1 and 2, showing potential effectiveness in treating advanced breast and ovarian cancers in patients with BRCA-1/2 mutations.
- - A Phase II trial found that although the objective response rate for rucaparib was relatively low (2% for IV and 15% for oral), a significant portion of patients demonstrated stable disease for over 12 weeks and some had responses lasting up to 567 days.
- - The study concluded that rucaparib is well tolerated and requires continuous dosing to achieve the best outcomes, particularly in patients with ovarian cancer.
Background: Human mass balance studies and the assessment of absolute oral bioavailability (F) are usually assessed in separate studies. Intravenous microdose administration of an isotope tracer concomitant to an unlabeled oral dose is an emerging technique to assess F. We report a novel double-tracer approach implemented for tofogliflozin combining oral administration of a radiolabel tracer with concomitant intravenous administration of a stable isotope tracer.
View Article and Find Full Text PDF